BidaskClub Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Strong Sell

Share on StockTwits

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday, September 19th.

JAZZ has been the topic of a number of other research reports. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Royal Bank of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, June 1st. Morgan Stanley downgraded Jazz Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $183.00 target price on the stock. in a report on Wednesday, July 11th. Cantor Fitzgerald set a $203.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 7th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Sunday, July 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $192.11.

NASDAQ:JAZZ traded up $3.44 during trading hours on Wednesday, reaching $158.82. 768,222 shares of the company were exchanged, compared to its average volume of 481,001. The company has a market capitalization of $10.16 billion, a P/E ratio of 16.61, a P/E/G ratio of 0.92 and a beta of 1.04. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $184.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.76 and a quick ratio of 3.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.23 by $0.26. The business had revenue of $500.48 million for the quarter, compared to the consensus estimate of $469.85 million. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. On average, sell-side analysts anticipate that Jazz Pharmaceuticals will post 11.7 EPS for the current fiscal year.

In related news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $175.70, for a total transaction of $35,140.00. Following the sale, the executive vice president now owns 25,572 shares of the company’s stock, valued at approximately $4,493,000.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Rick E. Winningham sold 16,639 shares of the firm’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $176.18, for a total value of $2,931,459.02. Following the sale, the director now directly owns 15,594 shares in the company, valued at approximately $2,747,350.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,778 shares of company stock worth $6,011,022. 3.90% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. Summit Trail Advisors LLC raised its position in Jazz Pharmaceuticals by 8,591.5% during the 1st quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock worth $102,000 after purchasing an additional 100,950 shares during the last quarter. Financial Gravity Wealth Inc. bought a new position in Jazz Pharmaceuticals during the 1st quarter worth $192,000. Tiverton Asset Management LLC bought a new position in Jazz Pharmaceuticals during the 2nd quarter worth $198,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals during the 2nd quarter worth $204,000. Finally, FDx Advisors Inc. bought a new position in Jazz Pharmaceuticals during the 2nd quarter worth $244,000. 92.52% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: How a Put Option Works

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.